List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Overview
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Companies Involved in Therapeutics Development
FibroGen Inc
GlaxoSmithKline Plc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Drug Profiles
daprodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDO-3055 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enarodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molidustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roxadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0463518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Dormant Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Discontinued Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Product Development Milestones
Featured News & Press Releases
Jun 25, 2021: Astellas receives positive CHMP opinion for EVRENZO (roxadustat) for adult patients with symptomatic anemia of chronic kidney disease
Apr 06, 2021: FibroGen provides additional information on Roxadustat
Apr 06, 2021: FibroGen announces FDA Advisory Committee to review Roxadustat new drug application tentatively Scheduled
Mar 01, 2021: FibroGen provides regulatory update on Roxadustat
Dec 21, 2020: Update on US regulatory review of roxadustat in anaemia of chronic kidney disease
Dec 18, 2020: Update on US regulatory review of roxadustat in anaemia of chronic kidney disease
Dec 02, 2020: FibroGen to present safety and efficacy analyses from roxadustat global phase 3 program at American Society of Hematology Annual Meeting
Nov 27, 2020: Astellas receives approval of EVRENZO (roxadustat) in Japan for the treatment of anemia of chronic kidney disease in adult patients not on dialysis
Nov 19, 2020: AstraZeneca demonstrates data on roxadustat at ASH 2020
Oct 22, 2020: FibroGen presents late-breaker abstract results on associations between hemoglobin levels and cardiovascular outcomes in roxadustat-treated patients with anemia of chronic kidney disease (CKD)
Oct 20, 2020: AstraZeneca to present update on Roxadustat at ASN Kidney Week 2020 Reimagined
Oct 19, 2020: New Roxadustat data in anemia of chronic kidney disease to be released at ASN Kidney Week 2020 Reimagined
Oct 14, 2020: FibroGen to present new efficacy and safety analyses from Roxadustat global phase 3 program at American Society of Nephrology Kidney Week 2020 Reimagined
Aug 26, 2020: Kyowa Kirin announces the approval of Duvroq in Japan by GSK for patients with renal anemia due to chronic kidney disease
Aug 26, 2020: Kyowa Kirin announces the approval of Duvroq in Japan by GSK for patients with renal anemia due to chronic kidney disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by FibroGen Inc, 2021
Pipeline by GlaxoSmithKline Plc, 2021
Pipeline by Japan Tobacco Inc, 2021
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021

Companies Mentioned
• FibroGen Inc
• GlaxoSmithKline Plc
• Japan Tobacco Inc
• Jiangsu Hengrui Medicine Co Ltd
• Taisho Pharmaceutical Holdings Co Ltd